Cargando…
Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia
Predicting the response to medical therapy and subsequently individualizing the treatment to increase efficacy or reduce toxicity has been a longstanding clinical goal. Not least within oncology, where many patients fail to be cured, and others are treated to or beyond the limit of acceptable toxici...
Autores principales: | Nersting, Jacob, Borst, Louise, Schmiegelow, Kjeld |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170275/ https://www.ncbi.nlm.nih.gov/pubmed/21906358 http://dx.doi.org/10.1186/1559-0275-8-8 |
Ejemplares similares
-
Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction
por: Schmiegelow, Kjeld, et al.
Publicado: (2014) -
Relating genomic variation to drug response in childhood acute lymphoblastic leukemia by multiplexed targeted sequencing
por: Wesolowska, Agata, et al.
Publicado: (2010) -
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions
por: Thastrup, Maria, et al.
Publicado: (2022) -
Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
por: Mogensen, Pernille Rudebeck, et al.
Publicado: (2020) -
Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
por: Gebhard, Anna, et al.
Publicado: (2023)